Get started
Author

Tomas Friman

Observed name: Friman, Tomas
Observed institution: Pelago Bioscience (Sweden)
ORCID: 0000-0001-6466-3856
Observed ORCID: 0000-0001-6466-3856
OpenAlex ID: A5002472937
Mass spectrometry-based Cellular Thermal Shift Assay (CETSA®) for target deconvolution in phenotypic drug discovery
2019 · Tomas Friman · Bioorganic & Medicinal Chemistry · 67
A Tale of Two Tails: Efficient Profiling of Protein Degraders by Specific Functional and Target Engagement Readouts
2021 · Alexey L. Chernobrovkin, Cindy Cázares-Körner, et al. · SLAS DISCOVERY · 28
CETSA MS Profiling for a Comparative Assessment of FDA-Approved Antivirals Repurposed for COVID-19 Therapy Identifies TRIP13 as a Remdesivir Off-Target
2020 · Tomas Friman, Alexey Chernobrovkin, et al. · SLAS DISCOVERY · 25
PDF
Mechanistic Insights into a CDK9 Inhibitor Via Orthogonal Proteomics Methods
2021 · J. Adam Hendricks, Nigel Beaton, et al. · ACS Chemical Biology · 14
PDF
In-depth characterization of Staurosporine induced proteome thermal stability changes
2020 · Alexey L. Chernobrovkin, Johan Lengqvist, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 7
PDF
Abstract 6853: A standardized drug selectivity profiling platform with a proteome coverage of more than 5,000 proteins
2025 · Tomas Friman, Tuomas Tolvanen, et al. · Cancer Research · 1
Abstract 5766: Fungal genomes in drug discovery: Application of CETSA to study the mechanism of action of brefeldin A
2024 · Tomas Friman, Benjamin M. Fontaine, et al. · Cancer Research · 1
Abstract 1848: The Cellular Thermal Shift assay and its applications in Target ID, MoA determination and biomarker discovery
2024 · Tomas Friman, Alexey Chernobrovkin, et al. · Cancer Research · 1
Abstract 1894: Proteome-wide target engagement and selectivity profiling of CDK2 inhibitors using CETSA®.
2026 · Tomas Friman, Merve Kacal, et al. · Cancer Research
Abstract 5180: Engaged but not degraded: Proteome-wide CETSA in degrader research
2026 · Tomas Friman, Sören Bruhn, et al. · Cancer Research
Abstract 3162: New hit compounds for p53 identified with a CETSA based high throughput screen
2025 · Tomas Friman, Merve Kacal, et al. · Cancer Research
Abstract 408: CETSA-based evaluation of non-degraded PROTAC targets
2025 · Tomas Friman, Tuomas Tolvanen, et al. · Cancer Research
Abstract 1413: Dissecting the biology of mutant p53 with the Cellular Thermal Shift Assay (CETSA)
2025 · Tomas Friman, Merve Kacal, et al. · Cancer Research
Abstract 3097: CETSA HT: Employing rapid high-throughput target engagement technology in primary screening of P53
2024 · Merve Kacal, Tomas Friman, et al. · Cancer Research
Abstract 3098: CETSA for navigating your chemistry and exploring the biology of protein degraders
2024 · Victoria Brehmer, Stina Lundgren, et al. · Cancer Research
Abstract 3096: CETSA Navigate HT: A new paradigm for high-throughput screening
2024 · Helena Almqvist, Victoria Brehmer, et al. · Cancer Research
Abstract 4723: Target engagement sheds light on difference in drug efficacy in breast cancer cell lines
2024 · Tomas Friman, Tuomas Tolvanen, et al. · Cancer Research
Abstract 646: Proteome wide target deconvolution of pharmacologically active natural products by CETSA® coupled to mass spectrometry
2024 · Tomas Friman, Tuomas Tolvanen, et al. · Cancer Research
Abstract 2924: Target identification, selectivity profiling and mechanistic insights of a Cdk9 inhibitor using complementary proteomics methods
2022 · Adam Hendricks, Nigel Beaton, et al. · Cancer Research
Works count: 21
Citation count: 144
H-index: 5
I10-index: 4
Year
Topic
Type